Inhibikase Therapeutics Stock Market Value
| IKT Stock | USD 2.31 0.30 14.93% |
| Symbol | Inhibikase |
Inhibikase Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inhibikase Therapeutics. If investors know Inhibikase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inhibikase Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.12) | Revenue Per Share 0.014 | Quarterly Revenue Growth (1.00) | Return On Assets (0.76) | Return On Equity (1.50) |
The market value of Inhibikase Therapeutics is measured differently than its book value, which is the value of Inhibikase that is recorded on the company's balance sheet. Investors also form their own opinion of Inhibikase Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Inhibikase Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inhibikase Therapeutics' market value can be influenced by many factors that don't directly affect Inhibikase Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inhibikase Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inhibikase Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inhibikase Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Inhibikase Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Inhibikase Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Inhibikase Therapeutics.
| 12/03/2022 |
| 11/22/2024 |
If you would invest 0.00 in Inhibikase Therapeutics on December 3, 2022 and sell it all today you would earn a total of 0.00 from holding Inhibikase Therapeutics or generate 0.0% return on investment in Inhibikase Therapeutics over 720 days. Inhibikase Therapeutics is related to or competes with DiaMedica Therapeutics, Milestone Pharmaceuticals, Seres Therapeutics, Oncolytics Biotech, Scpharmaceuticals, Tempest Therapeutics, and AN2 Therapeutics. Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinsons Disease and... More
Inhibikase Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Inhibikase Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Inhibikase Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.55 | |||
| Information Ratio | 0.0917 | |||
| Maximum Drawdown | 37.4 | |||
| Value At Risk | (9.09) | |||
| Potential Upside | 13.22 |
Inhibikase Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Inhibikase Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Inhibikase Therapeutics' standard deviation. In reality, there are many statistical measures that can use Inhibikase Therapeutics historical prices to predict the future Inhibikase Therapeutics' volatility.| Risk Adjusted Performance | 0.092 | |||
| Jensen Alpha | 0.5066 | |||
| Total Risk Alpha | (0.14) | |||
| Sortino Ratio | 0.1043 | |||
| Treynor Ratio | 0.3933 |
Inhibikase Therapeutics Backtested Returns
Inhibikase Therapeutics appears to be dangerous, given 3 months investment horizon. Inhibikase Therapeutics holds Efficiency (Sharpe) Ratio of 0.14, which attests that the entity had a 0.14% return per unit of risk over the last 3 months. By evaluating Inhibikase Therapeutics' technical indicators, you can evaluate if the expected return of 0.94% is justified by implied risk. Please utilize Inhibikase Therapeutics' Market Risk Adjusted Performance of 0.4033, risk adjusted performance of 0.092, and Downside Deviation of 5.55 to validate if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Inhibikase Therapeutics holds a performance score of 11. The company retains a Market Volatility (i.e., Beta) of 1.72, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Inhibikase Therapeutics will likely underperform. Please check Inhibikase Therapeutics' potential upside, and the relationship between the total risk alpha and kurtosis , to make a quick decision on whether Inhibikase Therapeutics' current trending patterns will revert.
Auto-correlation | 0.21 |
Weak predictability
Inhibikase Therapeutics has weak predictability. Overlapping area represents the amount of predictability between Inhibikase Therapeutics time series from 3rd of December 2022 to 28th of November 2023 and 28th of November 2023 to 22nd of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Inhibikase Therapeutics price movement. The serial correlation of 0.21 indicates that over 21.0% of current Inhibikase Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.21 | |
| Spearman Rank Test | -0.03 | |
| Residual Average | 0.0 | |
| Price Variance | 0.28 |
Inhibikase Therapeutics lagged returns against current returns
Autocorrelation, which is Inhibikase Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Inhibikase Therapeutics' stock expected returns. We can calculate the autocorrelation of Inhibikase Therapeutics returns to help us make a trade decision. For example, suppose you find that Inhibikase Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Inhibikase Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Inhibikase Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Inhibikase Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Inhibikase Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Inhibikase Therapeutics Lagged Returns
When evaluating Inhibikase Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Inhibikase Therapeutics stock have on its future price. Inhibikase Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Inhibikase Therapeutics autocorrelation shows the relationship between Inhibikase Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Inhibikase Therapeutics.
Regressed Prices |
| Timeline |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Inhibikase Stock Analysis
When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.